Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain)
- PMID: 29409816
- DOI: 10.1016/j.ejmg.2018.01.015
Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain)
Abstract
RAD51C and RAD51D have been defined as susceptibility genes for hereditary breast and ovarian cancer syndrome in several studies. In the present study, a mutation analysis of these genes was performed on non BRCA1/2 families. RAD51C and RAD51D genes were analyzed in 141 and 77 families, respectively. The analysis included direct sequencing and multiple ligation probe analysis. The RAD51C pathogenic variant c.404G > A was identified in a breast and ovarian cancer family (0.7%), while the RAD51D pathogenic variant c.694C > T was described in an ovarian cancer family (1.3%). Moreover, three unknown clinical significance variants were detected: c.307T > G in RAD51C, and c.413A > G and c.715C > T in RAD51D. No large genomic rearrangements (LGRs) were found. RAD51D carriers suffered from premenopausal ovarian tumors. These results increase our knowledge about the RAD51C and RAD51D mutation spectrum and support the notion that these genes should be included in the gene panel testing performed on patients with hereditary breast and ovarian cancer syndrome.
Keywords: Hereditary breast and ovarian cancer syndrome; RAD51C; RAD51D.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.PLoS One. 2015 Jun 9;10(6):e0127711. doi: 10.1371/journal.pone.0127711. eCollection 2015. PLoS One. 2015. PMID: 26057125 Free PMC article.
-
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.PLoS One. 2011;6(9):e25632. doi: 10.1371/journal.pone.0025632. Epub 2011 Sep 28. PLoS One. 2011. PMID: 21980511 Free PMC article.
-
Germline mutation in the RAD51B gene confers predisposition to breast cancer.BMC Cancer. 2013 Oct 19;13:484. doi: 10.1186/1471-2407-13-484. BMC Cancer. 2013. PMID: 24139550 Free PMC article.
-
Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.Klin Onkol. 2021 Winter;34(1):26-32. doi: 10.48095/ccko202126. Klin Onkol. 2021. PMID: 33657816 Review. English.
-
Genetic testing for RAD51C mutations: in the clinic and community.Clin Genet. 2015 Oct;88(4):303-12. doi: 10.1111/cge.12548. Epub 2015 Jan 7. Clin Genet. 2015. PMID: 25470109 Review.
Cited by
-
Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.J Natl Cancer Inst. 2019 Dec 1;111(12):1332-1338. doi: 10.1093/jnci/djz045. J Natl Cancer Inst. 2019. PMID: 30949688 Free PMC article.
-
Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.BMC Cancer. 2022 Dec 21;22(1):1337. doi: 10.1186/s12885-022-10456-z. BMC Cancer. 2022. PMID: 36544182 Free PMC article.
-
Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel). 2023 Jun 25;16(7):923. doi: 10.3390/ph16070923. Pharmaceuticals (Basel). 2023. PMID: 37513835 Free PMC article. Review.
-
Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma.Cancer Med. 2019 May;8(5):2545-2552. doi: 10.1002/cam4.2068. Epub 2019 Mar 18. Cancer Med. 2019. PMID: 30883040 Free PMC article.
-
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643. eCollection 2022. Front Oncol. 2022. PMID: 35785170 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous